Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Accumulated Expenses (2017 - 2025)

Serina Therapeutics' Other Accumulated Expenses history spans 6 years, with the latest figure at $350000.0 for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 76.77% year-over-year to $350000.0; the TTM value through Sep 2025 reached $350000.0, up 76.77%, while the annual FY2024 figure was $193000.0, 22.8% down from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $350000.0 at Serina Therapeutics, up from $185000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $350000.0 in Q3 2025 and bottomed at $5000.0 in Q2 2024.
  • The 4-year median for Other Accumulated Expenses is $189000.0 (2024), against an average of $176200.0.
  • The largest annual shift saw Other Accumulated Expenses plummeted 97.83% in 2024 before it soared 180.3% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $141000.0 in 2022, then surged by 77.3% to $250000.0 in 2023, then fell by 22.8% to $193000.0 in 2024, then soared by 81.35% to $350000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Other Accumulated Expenses are $350000.0 (Q3 2025), $185000.0 (Q1 2025), and $193000.0 (Q4 2024).